PIK3CA-AKT pathway predominantly acts in developing ipsilateral breast tumor recurrence long after breast-conserving surgery

[1]  E. Hirsch,et al.  Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer , 2021, Cancers.

[2]  F. Bertucci,et al.  Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  M. Omata,et al.  Identification of Clonality through Genomic Profile Analysis in Multiple Lung Cancers , 2020, Journal of clinical medicine.

[4]  M. Omata,et al.  Multi-regional sequencing reveals clonal and polyclonal seeding from primary tumor to metastases in advanced gastric cancer , 2020, Journal of Gastroenterology.

[5]  Nicholas J. Wang,et al.  Genomic landscape of ductal carcinoma in situ and association with progression , 2019, Breast Cancer Research and Treatment.

[6]  D. Arango,et al.  Pivotal Role of AKT2 during Dynamic Phenotypic Change of Breast Cancer Stem Cells , 2019, Cancers.

[7]  P. Cartron,et al.  Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer , 2019, Biochemical pharmacology.

[8]  X. F. Liu,et al.  [Clinical characteristics and prognosis of patients with ipsilateral breast tumor recurrence after breast conservation therapy]. , 2018, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[9]  T. D’alfonso,et al.  Current Concepts in Diagnosis, Molecular Features, and Management of Lobular Carcinoma In Situ of the Breast With a Discussion of Morphologic Variants. , 2017, Archives of pathology & laboratory medicine.

[10]  M. Omata,et al.  Genetic basis of a common tumor origin in the development of pancreatic mixed acinar-neuroendocrine-ductal carcinoma: A case report , 2017, Oncology letters.

[11]  M. Omata,et al.  Mutational analysis of multiple lung cancers: Discrimination between primary and metastatic lung cancers by genomic profile , 2017, Oncotarget.

[12]  Goto Taichiro,et al.  Mutational Analysis of Multiple Lung Cancers: Discrimination between Primary and Metastatic Lung Cancers by Genomic Profile , 2017 .

[13]  M. Omata,et al.  Touch imprint cytology with massively parallel sequencing (TIC‐seq): a simple and rapid method to snapshot genetic alterations in tumors , 2016, Cancer medicine.

[14]  M. Omata,et al.  Targeted and exome sequencing identified somatic mutations in hepatocellular carcinoma , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[15]  M. J. van de Vijver,et al.  Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period , 2016, Breast Cancer Research and Treatment.

[16]  M. Omata,et al.  Analysis of tumor-derived DNA in plasma and bone marrow fluid in lung cancer patients , 2016, Medical Oncology.

[17]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.

[18]  Michael B. Stadler,et al.  PIK3CAH1047R induces multipotency and multi-lineage mammary tumours , 2015, Nature.

[19]  May Yin Lee,et al.  Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity , 2015, Nature.

[20]  M. Omata,et al.  Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer , 2015, Molecular genetics & genomic medicine.

[21]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[22]  David Chen,et al.  ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.

[23]  V. Tjan-Heijnen,et al.  Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population-based cohort of 1143 patients. , 2013, European journal of cancer.

[24]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[25]  L. Tanoue,et al.  The National Comprehensive Cancer Network , 1998, Cancer.

[26]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[27]  M. Ishitobi,et al.  Early Response to Neo‐adjuvant Chemotherapy in Carcinoma of the Breast Predicts Both Successful Breast‐Conserving Surgery and Decreased Risk of Ipsilateral Breast Tumor Recurrence , 2010, The breast journal.

[28]  Emmanuel Barillot,et al.  High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers. , 2008, Journal of the National Cancer Institute.

[29]  F. Vicini,et al.  The use of molecular assays to establish definitively the clonality of ipsilateral breast tumor recurrences and patterns of in‐breast failure in patients with early‐stage breast cancer treated with breast‐conserving therapy , 2007, Cancer.

[30]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[31]  F. Vicini,et al.  Changes in temporal patterns of local failure after breast-conserving therapy and their prognostic implications. , 2004, International journal of radiation oncology, biology, physics.

[32]  S. Singletary,et al.  Classifying local disease recurrences after breast conservation therapy based on location and histology , 2002, Cancer.

[33]  B Fisher,et al.  Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. , 1985, The New England journal of medicine.

[34]  A. Luini,et al.  Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. , 1982, The New England journal of medicine.